MSWA
BMRN icon

Marshall & Sterling Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marshall & Sterling Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-91
Closed -$4.93K – 374
2025
Q3 		$4.93K Buy
+91
New +$5.2K ﹤0.01% 507

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marshall & Sterling Wealth Advisors's BMRN Position: Q4 2025 in Review

Marshall & Sterling Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 91 shares — an estimated $4.93K sold.

Marshall & Sterling Wealth Advisors first reported a position in BMRN in Q3 2025 and held it in 1 quarter. The position peaked at $4.93K in Q3 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Marshall & Sterling Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Marshall & Sterling Wealth Advisors sold 91 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $4.93K.
  • Marshall & Sterling Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Marshall & Sterling Wealth Advisors's BioMarin Pharmaceuticals position peaked at $4.93K in Q3 2025.
  • 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Marshall & Sterling Wealth Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.